Why it Matters

Patients taking oral cancer drugs face cost-sharing that often exceeds what insurance charges for the same treatment delivered intravenously. A hearing titled "Unequal Treatment: Addressing The Drivers Of Unaffordability For Oral Chemotherapy" was held before the House Oversight Subcommittee on Health Care and Financial Services on September 15.

The Big Picture

The hearing explored a structural disparity: oral chemotherapy is typically billed under pharmacy benefits with higher cost-sharing, while IV chemotherapy is billed under medical benefits with lower out-of-pocket costs. Patients face annual out-of-pocket costs of $10,000–$12,000 or more for oral drugs. The FDA has approved more than 50 oral anti-cancer medications, and between a quarter and a third of cancer drugs in development are estimated to be available only as a pill.

More than 40 states have enacted oral chemotherapy parity laws, but these do not reach self-funded employer plans, which cover roughly half of all cancer patients. The hearing examined the role of prior authorization, fail-first step therapy, and pharmacy benefit manager practices in driving affordability barriers.

Rep. Glenn Grothman (R-WI-6) introduced the Cancer Drug Parity Act on a bipartisan basis, which would require health plans to provide cost-sharing for oral anticancer drugs on terms no less favorable than for IV treatment. Senators Jerry Moran and Tina Smith introduced a companion bill in July. The administration has promoted drug pricing reforms through executive orders and the TrumpRx platform, though an NPR investigation found key oral cancer medications like Lynparza and Lenvima are not available on the site.

What They're Saying

The key dispute centers on whether federal action can close gaps that state laws cannot reach.

Dr. Sheetal Kircher, a practicing oncologist at Northwestern University's Robert H. Lurie Comprehensive Cancer Center, testified on behalf of cancer survivors, positioning clinical expertise alongside patient advocacy.

Anthony Wright of Families USA connected oral chemotherapy affordability to broader insurance coverage losses. Rep. Emily Randall (D-WA-6), filling in as ranking member, highlighted that up to 10 million people are estimated to have already lost health care coverage and noted the Trump administration canceled $160 million in funding for Washington State disease monitoring and vaccine programs.

Political Stakes

For Rep. Grothman, the hearing represents more a bipartisan priority since he has a family member with myeloma. The Cancer Drug Parity Act has backing from the International Myeloma Foundation, the Association for Clinical Oncology, and the American Cancer Society Cancer Action Network.

For the administration, the hearing occurred amid conflicting signals on drug pricing. While the Trump administration has promoted TrumpRx and pursued most-favored-nation pricing directives, critics argue the initiatives fall short. Rep. Randall noted that the administration's interim final rule on Medicaid work requirements conflicts with congressional intent to exempt cancer patients. The One Big Beautiful Bill Act exempted people with serious medical needs, but the CMS rule narrowed that exemption significantly.

The nonpartisan Congressional Budget Office projects that new Medicaid work rules will lead to 11.8 million people dropping Medicaid over the next decade, with 7 million projected not to find insurance elsewhere.

Yes, but

The administration has taken steps on pharmacy benefit manager transparency and pricing. In February, President Trump signed the Consolidated Appropriations Act, 2026, which included significant pharmacy benefit manager (PBM) reforms in Medicare Part D and Medicare Advantage programs. HHS Secretary Robert F. Kennedy Jr. stated at his confirmation hearing that Trump is "absolutely committed to fixing the PBMs."

However, the hearing examined how PBMs have shaped cost-sharing disparities between oral and IV chemotherapy. A clinician witness testified that financing frameworks have not evolved with cancer treatment modalities, and prior authorization and step therapy remain barriers even where parity laws exist.

What's Next

The hearing was the first on high drug costs held by the subcommittee and occurred nine months after the previous hearing. No immediate votes or follow-up hearings are scheduled based on available records.

The Bottom Line

Congress faces pressure to close gaps that state parity laws cannot reach, but the path forward depends on whether federal action prioritizes legislative fixes to insurance design or relies on executive drug pricing initiatives.

Access the Legis1 platform for comprehensive political news, data, and insights.

Spot something wrong? Report an issue with this article